Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-2060-016 | Other Identifier | MSD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Panel A: MK-2060 IV (20 minutes) | Experimental | Participants will receive a single dose of MK-2060 via intravenous (IV) infusion over 20 minutes on Day 1. |
|
| Panel B: MK-2060 IV (10 minutes) | Experimental | Participants will receive a single dose of MK-2060 via IV infusion over 10 minutes on Day 1. |
|
| Panel C: MK-2060 IV (5 minutes) | Experimental | Participants will receive a single dose of MK-2060 via syringe over 5 minutes on Day 1. |
|
| Panel D: MK-2060 IV (2.5 minutes) | Experimental | Participants will receive a single dose of MK-2060 via syringe over 2.5 minutes on Day 1. |
|
| Panel E: MK-2060 IV (1 minute) | Experimental | Participants will receive a single dose of MK-2060 via syringe over 1 minute on Day 1. |
|
| Placebo |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK-2060 | Biological | Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With An Adverse Event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants that experience an AE will be reported. | Up to 134 days |
| Number of Participants Discontinuing the Study Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants that discontinue the study due to an AE will be reported. | Up to 134 days |
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC0-inf) | Plasma samples will be collected at pre-specified time points pre- and post-dose to assess AUC0-inf. | Predose and at designated time points post dose up to 120 days |
| Maximum Observed Plasma Concentration (Cmax) of MK-2060 |
Not provided
Inclusion Criteria:
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Advanced Pharma CR, LLC ( Site 0002) | Miami | Florida | 33147 | United States | ||
| Alliance for Multispecialty Research, LLC ( Site 0001) |
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020246 | Venous Thrombosis |
| ID | Term |
|---|---|
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants will receive a single dose of saline via IV infusion or syringe over MK-2060-matched time period on Day 1. |
|
| Placebo | Biological | Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization. |
|
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Cmax. |
| Predose and at designated time points post dose up to 120 days |
| Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168) | Plasma samples will be collected at pre-specified time points pre- and post-dose to assess AUC0-168 hours. | Predose and at designated time points post dose up to 120 days |
| Plasma Concentration of MK-2060 at 168 Hours (C168) | Plasma samples will be collected at pre-specified time points pre- and post-dose to assess C168 hours. | Predose and at designated time points post dose up to 120 days |
| Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060 | Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Tmax. | Predose and at designated time points post dose up to 120 days |
| Plasma Elimination Terminal Half-life (t ½) of MK-2060 | Plasma samples will be collected at pre-specified time points pre- and post-dose to assess t½ . | Predose and at designated time points post dose up to 120 days |
| Apparent Oral Clearance (CL/F) of MK-2060 | Plasma samples will be collected at pre-specified time points pre- and post-dose to assess CL/F. | Predose and at designated time points post dose up to 120 days |
| Plasma Apparent Volume of Distribution (Vz/F) of MK-2060 | Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Vz/F. | Predose and at designated time points post dose up to 120 days |
| Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060 | Plasma samples will be collected at baseline and pre-specified time points post-dose to assess aPTT values. The fold change from baseline will be reported. | Baseline and up to 120 days |
| Knoxville |
| Tennessee |
| 37920 |
| United States |